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Production of Human Sebocytes
Aniko Dozsa1,2, Balazs Dezso3, Balazs I. Toth4, Attila Bacsi5, Szilard Poliska1, Emanuela Camera6,
Mauro Picardo6, Christos C. Zouboulis7, Tama´s Bı´ro´4, Gerd Schmitz8, Gerhard Liebisch8, Ralph Ru¨hl1,
Eva Remenyik9 and Laszlo Nagy1,10
The transcriptional basis of sebocyte differentiation and lipid production is mostly unclear. Peroxisome
proliferator–activated receptor gamma (PPARg), a lipid-activated transcription factor, has been implicated in
differentiation and lipid metabolism of various cell types. Here, we show that PPARg is differentially expressed in
normal and pathological human sebocytes and appears to have roles in their differentiation and lipid production.
We used laser-microdissected normal and pathological human sebaceous glands (SGs) and SZ95 cells
(immortalized sebocyte cell line) analyzed by real-time quantitative PCR and immunohistochemistry. Lipids were
analyzed by quantitative fluorimetry– and mass spectrometry–based approaches. We have observed that PPARg
and its target genes, ADRP (adipose differentiation–related protein) and PGAR (PPARg angiopoietin–related
protein), are expressed in sebocytes and show association with their level of differentiation. Also, PPARg is present
in normal and hyperplastic SG, whereas its expression levels are decreased in SG adenoma and SG carcinoma
cells, reflecting a maturation-linked expression pattern. Furthermore, in SZ95 sebocytes, naturally occurring lipids,
including arachidonic acid and arachidonic acid keto-metabolites (e.g., 5-KETE (5-oxo-6E,8Z,11Z,14Z-eicosatetrae-
noic acid), 12-KETE (12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid)), appear to regulate PPARg signaling pathways,
which in turn modulate phospholipid biosynthesis and induce neutral lipid synthesis. Collectively, our findings
highlight the importance of endogenous ligand-activated PPARg signaling in human sebocyte biology and suggest
that PPARg might be a promising candidate for the clinical management of SG disorders.
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INTRODUCTION
Investigating the function of the sebaceous gland (SG) under
normal and pathological conditions is a major research
interest in dermatology. This includes investigations into the
transcriptional mechanisms that regulate lipid metabolism and
inflammatory responses of sebocytes (Toth, et al., 2011).
Identification of specific regulatory mechanisms and key
actors in these processes is essential to fully understand the
normal physiological function and to clarify the
pathophysiological involvement of SGs. A particularly
relevant area of research is the regulation of gene expression
by transcription factors responding to changes in fatty
molecules and therefore linking metabolic processes to gene
regulation.
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Peroxisome proliferator–activated receptors (PPARs) are
lipid-activated nuclear receptors, having roles in sebaceous
lipogenesis and differentiation (Alestas, et al., 2006; Trivedi,
et al., 2006). In particular, the lipid-activated nuclear receptor,
peroxisome proliferator–activated receptor gamma (PPARg)
has key roles in the adipocyte, liver, macrophage, and
dendritic cell differentiation as well as in lipid metabolism
(Forman et al., 1995; Tontonoz et al., 1998; Kim et al., 2001
Ferre, 2004; Knouff and Auwerx, 2004; Szatmari et al., 2006;
Nagy et al., 2012). In addition, PPARg is expressed in SGs
(Deplewski and Rosenfield, 2000; Kim et al., 2001; Zouboulis
et al., 2005; Alestas et al., 2006; Trivedi, et al., 2006; Michalik
and Wahli, 2007; Zhang et al., 2006). Furthermore, PPARg
may be an important molecule in acne vulgaris, the most
frequent SG-related dermatosis with abnormal lipid storage
and inflammation (Anttila et al., 1992; Zouboulis, 2003;
Zouboulis et al., 2005; Alestas et al., 2006; Trivedi et al.,
2006). Arachidonic acid (AA) markedly enhances lipid synthesis
in SZ95 sebocytes (Wrobel et al., 2003; Alestas et al., 2006;
Toth et al., 2009; Geczy et al., 2010), and some of this
induction might be regulated via PPARg (Alestas et al., 2006).
Furthermore, AA is metabolized via various pathways to a
large variety of derivatives (Harizi et al., 2008), and selected
metabolites act as potent endogenous ligands of PPARs, espe-
cially of PPARg in fibroblasts and adipocytes (Forman et al.,
1995; Kliewer et al., 1997). However, the nature and identity of
endogenous ligands that activate PPARg in the skin are not
known. Potential ligands of PPARs include fatty acids, various
eicosanoids, and other lipids found in the skin and also in SGs.
(Trivedi, et al., 2006). Previous studies have shown that AA can
activate PPARg; however, it is highly likely that not AA but some
of its metabolites are bioactive mediators of PPARg activation
(Kliewer et al., 1995; Thuillier et al., 2002; Alestas et al. 2006).
These findings prompted us to systematically assess the role of
PPARg in human sebocytes. We also sought to identify endo-
genous PPARg ligands among AA derivatives, which activate the
receptor, along with gathering evidence on target gene expres-
sion and roles in differentiation and lipid metabolism both in situ
in normal and pathological SGs and in vitro in a model cell line.
To address these issues, including the expression levels of
PPARs and the presence of PPARg in normal and pathological
conditions, we have examined the expression of this transcrip-
tion factor in sebocytes in two different human SG model
systems: (i) in laser-micro-dissected SG from fresh frozen
tissues; and (ii) in a human immortalized SG cell line, namely
SZ95. We also determined PPARg expression pattern in
sebaceous hyperplasia, adenoma, and carcinoma tissues. We
found that AA and AA-derived keto-metabolites apparently
modulate PPARg activity, which appears to be important in
the regulation of SG differentiation and lipid biosynthesis.
RESULTS
PPARc and its target genes are expressed in normal human
SGs in situ
First, we determined the expression level of PPARg and markers
of its activity in human SGs in situ. Immuno-labeling identified
PPARg protein expression predominantly in the nuclei of
normal SGs of skin biopsies obtained from healthy volunteers
(n¼10; Figure 1a). In addition, SGs were isolated from donors
of healthy (n¼ 5) and pathological (n¼2) human skin tissues
by laser microdissection and mRNA levels of PPARg were
examined by quantitative real-time PCR. The expression of
PPARg mRNA was higher in healthy SG than in pathological
(hyperplasia and adenoma) samples, although the latter was
available only in limited numbers and therefore no definitive
conclusions can be drawn (Supplementary Figure S1a online).
It is generally accepted that PPARg activity is indicated by
the mRNA expression of its target genes, including the adipose
differentiation–related protein (ADRP) and PPARg
angioprotein–related protein (PGAR), as established in other
cell types (Forman et al., 1995; Szanto et al., 2004; Nagy and
Szanto, 2005; Szatmari et al., 2006; Varga and Nagy, 2008).
We also found that laser-microdissected SG samples from
healthy individuals express ADRP and PGAR mRNA at high
levels (Supplementary Figure S1a online). These data suggest
that PPARg and also its target genes are present in human SGs.
PPARc expression correlates with the differentiation stage of
sebocytes
Next we sought to define the role of PPARg in the process of
sebocyte differentiation. Therefore, we investigated SGs from
human biopsies obtained from patients with benign or
malignant SG lesions. In order to document the differentiation
stages of sebocytes within SG, we immunostained sections
and measured mRNA for Ki67, a well-known marker of active
cell cycle, and for the androgen receptor (AR). Also, the grade
of differentiation of sebocytes within the SG was classified.
Immunostaining was scored semi-quantitatively according to
previous reports (Tsujita-Kyutoku et al. 2003, Cottle et al.,
2013) (Figure 1, Figure 1b and Supplementary Table S1
online). In order to extend these analyses, we used reference
markers for basal immature sebocytes p63 protein (Tsujita-
Kyutoku et al., 2003). PPARg was present at high levels in
sebocytes of all samples (n¼10) from patients with SG
hyperplasia (Figure 1a). Both the Ki67 and p63 markers stain
nuclei of immature sebocytes located at the basal layers of
normal SG, whereas AR was incorporating predominantly the
basal and suprabasal cell layers and, to a lesser extent, the
central cells, as well. By contrast, PPARg was detectable in
terminally differentiated mature sebocytes located in the
central regions of normal SGs but was hardly detectable in
basal layer cells. Double immunolabeling for Ki67 along with
PPARg clearly demonstrated the predominantly different
localizations for these two nuclear proteins discriminating
the immature (Ki67 positive) cells from the mature (PPARg
positive) ones, which appeared to be the rule for these marker
expressions in normal and hyperplastic SGs. We also analyzed
the samples of SG tumors. When compared with normal and
hyperplastic SGs, cells of sebaceous adenomas (n¼10) gen-
erally expressed decreased amounts of PPARg, which
appeared to decrease further in malignant tissues and sebac-
eous carcinomas (n¼9) and down to hardly detectable levels
in poorly differentiated neoplastic cells. In the same SG
carcinoma samples, the un-affected normal tissue parts with
intact SGs retained the significantly high PPARg-specific
nuclear protein expression levels (Supplementary Figure S1c
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Figure 1. Comparative analyses of protein and mRNA expression patterns of peroxisome proliferator–activated receptor gamma (PPARc) in conjunction with
compartment-associated reference markers for human normal and pathological sebaceous glands (SGs) and laser-microdissected healthy SG compartments.
(a) Hematoxylin and eosin–stained histology and the corresponding immunoprofiles in human skin tissues for PPARg, p63, androgen receptor (AR), and Ki67
nucleo-protein expressions of various SG types, respectively. Black arrows indicate representative positive cells (brown or purple nuclei). Note the comparable
expression patterns of PPARg (second column) and the reference markers p63 and Ki67 (third and fifth columns) in normal and hyperplastic SGs demonstrating
clear discrimination for the PPARgþ -differentiated sebocytes with vacuolated (lipid rich) cytoplasm from the thin layers of p63/Ki67þ immature basal sebocytes
exhibiting inconspicuous cytoplasm. In contrast, the sebaceous adenoma samples (third-line panel) show an increase number of p63/Ki67þ basal immature
(proliferating) sebocytes, on account of differentiated sebocytes as the latter cell types show a relative reduction in number with decreased PPARg expression
intensities—albeit their morphologies still exhibit lipid droplets with no pleomorphism reflecting terminal maturation. As compared with adenoma, sebaceous
carcinomas show prominent decrease in the number and expression intensities of PPARgþ neoplastic malignant cells in the function of differentiation levels
(i.e., grade of pleomorphism) of lesional sebocytes. Accordingly, poor differentiation is indicated by cellular pleomorphism and significantly increased Ki67þ cells
with no PPARg expression, whereas in well or moderately differentiated regions (within the same tumor) PPARgþ cells can be identified. This phenomenon is
clearly demonstrated on the PPARg–Ki67 double-labeled images by means of both immuno-peroxidase and immunofluorescence methods (lower right images).
(b) Summary of immunostaining and differetiation grade of sebocytes in the lesion. Samples were evaluated semi-quantitatively for distinct sebaceous glands/SG
tumors, reflecting the % of positive cells:  , negative; 1þ , 0–20%; 2þ , 20–50%; 3þ , 50–75%; 4þ , 75–100%. (c) Basal and subrabasal (white column) and
central (black column) cell layers of normal SG samples were laser microdissected (n¼ 5 samples from 5 donors, i.e., S6: sample 6), for mRNA analysis.
Bar¼100mm. (d) PPARg, ADRP (adipose differentiation–related protein), PPARg angioprotein–related protein (PGAR), AR, and Ki67 expression at the mRNA level.
The values shown are mean±SD of three separate measurements. *Po0.05 was considered as significant change.
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online). The decreased level or the absence of PPARg protein
correlated with an increase of Ki 67- and p63-positive
neoplastic cells of sebaceous carcinoma cases, reflecting the
ratio of more differentiated (i.e., PPARg-positive cells with lipid
droplets) and the less mature (poorly differentiated, basaloid)
cellular components of the tumors in all the cases studied.
Double immunostaining with Ki67 and PPARg confirmed that
the more differentiated carcinoma cells expressed preferen-
tially PPARg without Ki67, and the Ki67-positive proliferating
pleomorphic neoplastic cells did not exhibit PPARg (Figure 1,
last image at lower right). In contrast, the expression pattern of
AR at protein levels generally did not show such an obvious
and clear distinction in well-differentiated and poorly differ-
entiated cellular components of sebaceous carcinomas studied
so far. However, it was expressed in high proportion of
adenoma cells in all cases (Figure 1, middle).
We then corroborated our results by investigating the
PPARg expression pattern and its signaling pathway during
normal sebocyte differentiation. Therefore, terminally differ-
entiated normal SG cells (i.e., from the central zone of the
gland) and immature cells (from the basal-parabasal zones)
were collected separately by in situ laser microdissection from
fresh frozen human skin tissues from the facial region of five
different donors. Subsequently, mRNA expressions of PPARg,
ADRP, PGAR, Ki67, and AR were measured (Figure 1d).
PPARg, ADRP, and PGAR were expressed at low levels in
basal cells, whereas higher expression was detected in the
well-differentiated sebocytes of the central zone 4/5 samples
(PPARg) and 3/5 samples (ADRP, PGAR). In contrast, Ki67 and
AR mRNA was expressed at high levels in the basal cell layer
and was expressed to a lesser degree or not detectable in
central cells (AR 4/5 samples, Ki67,5/5 samples). These data
together with findings from the 10 samples analyzed by
immunohistochemisty indicated that PPARg may be used as
a potential marker of sebocyte differentiation.
Active PPARc is present in human SZ95 sebocytes
To further explore how PPARg functions in sebocytes, we used
a well-established human SG cell line, SZ95 sebocytes
(Zouboulis et al., 1999). Expressions of the three PPAR iso-
forms were detected at the mRNA level in SZ95 sebocytes
(Supplementary Figure S1b online). Remarkably, PPARg
mRNA expression was highest among the PPAR isoforms.
We measured the mRNA levels of retinoid X receptor (RXR)
isoforms, which are the heterodimerization partners of PPARg.
Confirming a previous report (Tsukada et al., 2000), RXRa
appeared to be the dominant RXR subtype in SZ95 sebocytes
(Supplementary Figure S1b online).
Next, we investigated PPARg activity in SZ95 sebocytes.
We treated SZ95 sebocytes with the synthetic PPARg agonist
rosiglitazone (RSG) and measured the mRNA levels of two
target genes, PGAR and ADRP. RSG (1–10mM) induced
significant upregulation of PGAR (ca. 32-fold) and ADRP
(ca. 3-fold). The RXR agonist LG100268 (20–200 nM) also
increased PGAR (ca. 46-fold) and ADRP (ca. 2-fold) expres-
sions (Supplementary Figure S1b online). Administration of a
PPARg inhibitor, GW9662, markedly abrogated the RSG-
induced target gene induction in a dose-dependent manner
(1–10mM). These data collectively suggest that PPARg is active
in human SZ95 sebocytes. This confirms our previous
observations (Dobrosi et al., 2008). Our findings also
suggest that PPARg and RXRa are likely to act on the same
molecular pathways.
AA regulates sebocyte differentiation, in part, via PPARc-coupled
signaling pathways
To further explore the biological consequences of PPARg
stimulation on SG biology, we also investigated the functional
role of PPARg in SZ95 sebocytes. Sebocyte differentiation is
characterized by the synthesis of various lipids, among which
neutral lipids represent the major part (Rosenfield et al., 1998;
Zouboulis et al., 1999). Confirming our previous results (Alestas
et al., 2006; Toth et al, 2009), first we showed that AA, one of
the most effective differentiation inducer of SZ95 sebocytes,
markedly enhanced lipid synthesis of the cells (Figure 2a).
Quantitative Nile red-based fluorescence assay was performed,
which showed that AA induced neutral lipogenesis in SZ95
sebocytes in a dose-dependent manner (Figure 2c).
Intriguingly, the PPARg agonist RSG also induced sebaceous
neutral lipid synthesis in SZ95 sebocytes (albeit at a lower
potency than AA) (Figure 2a and c). We then assessed the
involvement of PPARg in AA-induced biological changes. AA
treatment of the cells resulted in a marked upregulation of the
mRNA expression levels of the PPARg target genes (PGAR and
ADRP), the effect of which could be fully abrogated by a
PPARg-specific antagonist GW9662 (Figure 2d and e). More-
over, the lipid synthesis–promoting activity of AA was also
inhibited partially by a PPARg antagonist. Finally, we found
that AA treatment also upregulated the mRNA level of PPARg
(Figure 2b). In order to determine the specificity of AA
treatment, we also treated the sebocytes with oleic acid and
palmitoleic acid, interestingly both induced lipid accumula-
tion and PGAR and ADRP expression, but neither effect was
inhibited by PPARg antagonist treatment (Figure 2d and e),
suggesting that PPARg is not involved in these responses.
AA regulates the production of selected lipid molecules via PPARc
To further explore how PPARg activation affects lipid produc-
tion in sebocytes, we treated the cells with AA (25mM) and
with a PPARg antagonist GW9662 (10mM) simultaneously for
24 hours and then analyzed the major neutral lipids and
specific membrane lipids. We determined the relative abun-
dance of major neutral lipid classes, such as triglycerides (TG),
free fatty acids (FFA), cholesterol esters (CE), cholesterol (CH),
wax esters (WE), and squalene (SQ) using high-performance
thin layer chromatography (HPTLC) (Figure 3a) followed by
densitometric analyses. Quantitative determinations of AA
were performed by HPLC coupled with tandem mass spectro-
metry (HPLC-QqQ/MS), whereas concentrations of SQ and
CH and the relative abundance of AA-induced diglycerides
(DG) and TG were determined by HPLC-ToF/MS.
Densitometric analyses of HPTLC spots showed that TG
levels were significantly elevated by AA, and this induction
was inhibited by a PPARg inhibitor (Figure 3a). Substrate
concentration of AA was determined quantitatively, and
exposing sebocytes to AA resulted in a significant elevation
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of AA concentration in the cells, while co-administration of
GW9662 appeared not to influence these cellular levels of
free AA (Figure 3b). Biosynthesis of TG is a multistep process
that involves different lipid intermediates. To gain insight into
the mechanisms involving PPARg activation, we determined
the relative abundance of AA-induced DG and TG by HPLC-
MS analyses. The AA containing DG 40:8 was significantly
induced by AA, while GW9662 did not influence DG 40:8
levels. The levels of the TG 60:12, representative of the AA-
containing TG, were induced to a significant extent
(Figure 3c). When AA was co-administered with a PPARg
antagonist, this induction of TG 60:12 was inhibited, which is
consistent with the HPTLC results concerning the total TG
(Figure 3a–c).
The other neutral lipids that were influenced by the addition
of AA were CE and WE. AA elevated WE levels; however, no
effect of the PPARg antagonist on this was observed. Addi-
tionally, AA had no significant effect on the total CE levels,
regardless of the presence of the PPARg antagonist (densito-
metric results not reported). Interestingly, basal CH level was
significantly decreased by the PPARg antagonist GW9662 as
demonstrated by the quantitative analysis of CH by HPLC-MS
(Figure 3b). In contrast, concentration of SQ determined by
HPLC-MS was not affected by AA alone or in combination
with the PPARg antagonist GW9662 (data not shown).
Next, using direct flow injection electrospray ionization
tandem mass spectrometry (ESI-MS/MS), 10 main specific
membrane lipid groups were assessed: phosphatidylinositol
(PI), lysophosphatidylcholine (LPC), phosphatidylcholine,
sphingomyelin, dihydrosphingomyelin, phosphatidylethanola-
mine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG),
ceramide, and glucosylceramide. AA had no significant effect
on ceramides (CER) and glucosylceramides. Among the other
eight measured membrane lipid groups, AA induced signifi-
cant alterations in the levels of 136 of the 198 measured lipid
species (Figure 3d). Importantly, the presence of the PPARg
inhibitor GW9662 significantly prevented the action of AA on
eight lipid species (Figure 3d). Among these molecules, AA
decreased the level of seven types of PI, whereas it upregu-
lated the expression of 18:2 LPC. These findings suggest that
Figure 2. Arachidonic acid (AA) induces upregulation of peroxisome
proliferator–ctivated receptor gamma (PPARc) and PPARc target genes
resulting in differentiation of SZ95 sebocytes. (a–c) SZ95 sebocytes were
treated for 24 hours or (d, e) 6 hours with 1–10mM rosiglitazone (RSG), 1–10mM
GW9662 (PPARg inhibitor), 5–50mM AA, 5–100mM oleic acid (OA), 5–100mM
palmitoleic acid (PA), and combinations of these ligands. (a) Intracellular lipids
were assessed by Nile red labeling following fluorescence microscopy.
Bar¼50mM (c) Quantitative measurement of neutral and polar lipids by FLIPR
fluorescent microplate reader. Data (means±SD) are presented as the
percentage values of quadruplicates; the value of the vehicle-treated control
group was defined as 100%. Two additional experiments yielded similar
results. (b, d, e) mRNA expression of PPARg, PPARg angioprotein–related
protein (PGAR), and adipose differentiation–related protein (ADRP). AA
increased the mRNA expression of PGAR and ADRP in a dose-dependent
manner, which was inhibited by GW9662. Mean±SD of three biological
replicates measured in triplicates. *Po0.05 was considered as significant
change compared with vehicle-treated control or ligand-treated cells.
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AA regulates the metabolism of these molecules in a PPARg-
dependent fashion.
Therefore, the AA-coupled PPARg pathway may contribute
to the generation of major neutral lipids and membrane
phospholipid production. With this, we comprehensively
analyzed lipid changes upon AA treatment and sorted out
the ones requiring PPARg activation.
The above data collectively suggest that (i) PPARg is indeed
active in cultured SZ95 sebocytes where its activation resulted
in a lipogenic action; (ii) AA acts as a PPARg agonist in SZ95
sebocytes; (iii) the effect of AA to enhance lipogenesis and
hence sebaceous differentiation was only partially mediated
by the activation of PPARg and the related signaling
(and hence other, PPARg-independent signal transduction
mechanisms are most likely involved); and (iv) PGAR and
ADRP can be regulated by other lipid mediators, and AA’s
effect is only partly PPARg dependent. As an additional
control, we measured cell line viability with MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide),
and we found that none of the applied ligands induced cell
death (Supplementary Figure S1b online).
AA metabolites activate PPARc and induce lipogenesis in
sebocytes
AA can be metabolized to a plethora of signal lipids (Harizi
et al., 2008). Therefore, we assessed whether certain AA
metabolites can also induce similar cellular responses on
human sebocytes. SZ95 sebocytes were treated with AA for
6 hours and an HPLC-MS approach was then used to
quantitatively determine the levels of AA-derived signaling
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Figure 3. Arachidonic acid (AA)-induced peroxisome proliferator–activated receptor gamma (PPARc) activation changes selected lipid classes in SZ95
sebocytes. Cells were treated for 24 hours with 25mM AA or AA 25mM plus 10mM GW9662. (a) High-performance thin layer chromatography and densitometric
analysis of triglyceride (TG) bands (average±SD of normalized intensity). (b) Quantitative determinations of AA and cholesterol (CH) by HPLC-MS with triple
quadrupole (QqQ) analyzer (average±SD of normalized concentrations). (c) HPLC-MS analyses with a time of flight (ToF) MS detector of AA containing
diglycerides (DG) 40:8 (20:4/20:4) and TG 60:12 (20:4/20:4/20:4). AA elevated the levels of DG and TG, but only TG 60:12 induction was significantly inhibited
by the PPARg antagonist GW9662. (d) Electrospray ionization tandem mass spectrometry (ESI-MS/MS) analysis of 10 membrane lipid classes: phosphatidylinositol
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species, where AA effect was inhibited by PPARg antagonist GW9662. Color bar defines concentration fold change. Different fatty acid chain length and saturation
of lipids are shown in numbers. Data are expressed as mean of three independent determinations of three independent biological replicates (*Po0.05). CE,
cholesterol esters; FFA, free fatty acids; WE, wax esters.
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lipids. Among the several candidates, we primarily focused on
eicosanoids, which have a proven ability to activate PPARg
like 5-KETE (5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid),
12-KETE (12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid), and
15-KETE (15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid).
Upon AA treatment, we detected increased concentrations
of 5-KETE, 12-KETE, and 15-KETE (Figure 4a). Furthermore,
these endogenous AA metabolites administered at a concen-
tration of 5mM (Shiraki et al., 2005; O’Flaherty et al., 2005)
significantly elevated sebaceous lipid synthesis (Figure 4b and
c), and in case of 5-KETE and 12-KETE, neutral lipid production
was partially inhibited by PPARg antagonist GW9662. To
explore whether these molecules also activate PPARg in
another set of experiments, SZ95 sebocytes were treated
similarly and expressions of PPARg target genes were then
assessed. We found that 5-KETE, 12-KETE, and 15-KETE
significantly increased the gene expression levels of PGAR
and ADRP. However, the PPARg antagonist GW9662 was able
to inhibit the induction of PGAR only in the case of 12-KETE
and 5-KETE (Figure 4d) and the induction of ADRP in the case
of 12-KETE (Figure 4e). Taken together, these findings indicate
that AA-metabolites have a role in sebaceous lipogenesis and
that 12-KETE and 5-KETE are likely to signal via PPARg.
DISCUSSION
The fact that PPARg is expressed in normal SG, primary
sebocytes, and SZ95 sebocytes has been well documented
(Smith and Thiboutot, 2008). However, it was not known what
might be the role of this transcription factor in situ. We
intended to extend these studies by the combination of using
laser microdissection and cellular models. We found that
PPARg appears to correlate with the more differentiated state
of sebocytes. This was confirmed by using established markers
of cell cycle activity and differentiation, such as Ki67, p63,
and AR molecules. Co-staining of Ki67 and PPARg molecules
gave indication of an inverse relationship. AR was expressed
mostly in basal and parabasal cell layers and showed an
overlap with PPARg expression in the parabasal layer. We also
compared the expression of these molecules in pathologies. In
sebaceous hyperplasia, we found that the expressions of
PPARg and the other markers were essentially the same as
in normal SG. In contrast, the proportion of cells expressing
PPARg in sebaceous adenoma and sebaceous carcinoma is
lower, but the proportion of Ki67 and p63-positive cells is
higher (Figure 1a). Recently, Cottle et al. (2013) described the
expression of AR (basal, parabasal layer), Ki67 (some is basal
layer), and PPARg (intermediate, ie outer central layer) in
healthy SG of murine origin and gathered similar findings with
AR in SG tumors. Additionally, the differentiation stage of
carcinomas appeared to be correlated with the presence of
PPARg in tumor cells (Supplementary Figure S1c online).
These findings are consistent with the results obtained using
uroepithelial carcinoma cells, in which the presence of PPARg
changed consistently with the differentiation state of carci-
noma cells (Nakashiro et al., 2001) and also (estrogen/
progesterone) receptor expression in breast cancers (Payne
et al., 2008). This suggests that PPARg might be a reliable
diagnostic marker of sebocyte differentiation state.
As far as the function of the receptor is concerned, we had to
rely on a model cell line. Using a model of AA-treated
differentiated sebocytes (Wrobel et al., 2003; Alestas et al.,
2006), we observed that the lipid-rich SZ95 sebocytes
expressed high levels of PPARg and also its target genes
PGAR and ADRP (Supplementary Figure S1b online), consis-
tent with our previous finding, where the AEA (N-arachido-
noyl-ethanolamine; endocannabinoid)-induced differentiation/
lipid production was shown to be induced via PPARg (Dobrosi
et al., 2008). In addition, we provide pharmacological
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Figure 4. Arachidonic acid (AA)-derived metabolites 5-KETE (5-oxo-
6E,8Z,11Z,14Z-eicosatetraenoic acid) and 12-KETE (12-oxo-5Z,8Z,10E,14Z-
eicosatetraenoic acid) are potential endogenous lipogenic activators of
peroxisome proliferator–activated receptor gamma (PPARc) in SZ95
sebocytes. (a) SZ95 sebocytes treated for 6 hours with 25mM AA and then
intracellular concentrations of its keto-metabolites (5, KETE, 12-KETE, 15-KETE
(15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid)) were measured with HPLC-MS
technology. Heat map of concentrations; color bar defines concentration fold
change. (b–e) SZ95 sebocytes were treated with 10mM (b, c) or 1 mM
rosiglitazone (RSG) (d, e), 25mM AA, 10mM GW9662, 5mM 5-KETE, 5mM
12-KETE, 5mM 15-KETE, and combination of these ligands with a PPARg-
antagonist. (b, c) Quantitative measurement of neutral and polar lipids by
FLIPR fluorescent microplate reader after 24 hours of treatment. Data
(means±SD) are presented as percentage values; the value of the vehicle-
treated control group was defined as 100%. Two additional experiments
yielded similar results. mRNA expression of PPARg target genes PGAR (PPARg
angioprotein–related protein) (d) and ADRP (adipose differentiation–related
protein) (e). Data are expressed as mean±SD of triplicate determinations of
three independent biological replicates (Po0.05). Po0.05 was considered as
significant change; *compared with vehicle-treated control; #compared with
the treated group without the presence of GW9662.
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evidence indicating that the specific PPARg antagonist
GW9662 dose dependently inhibited this AA-mediated target
gene induction (Supplementary Figure S1b online). Also, the
RXR agonist LG100268 induced ADRP and PGAR mRNA
elevation. Our interpretation of these data is that both PPARg
and RXRa are active in human SZ95 sebocytes, and possibly
are heterodimer partners, or act on the same molecular
pathways (Supplementary Figure S1b online).
Previous research has shown that RSG-activated PPARg has
a role in sebaceous lipid production, a marker of sebocyte
differentiation (Trivedi et al., 2006). In our study, both the
natural ligand precursor, AA, and the synthetic ligand, RSG,
induced sebaceous lipogenesis (Figure 2b) similar to previous
results (Trivedi et al., 2006). This suggests that PPARg-induced
gene activation coincides with sebocytes’ neutral lipid
production. We analyzed neutral lipids, which are the major
components of the sebaceous lipid mixture, along with
membrane lipid species (Figure 3b). We found that TG levels
were significantly elevated by AA, and this effect was inhibited
by PPARg antagonist. It was previously shown that PPARg
ligand RSG induced TG production (Trivedi et al., 2006).
These findings indicate that the elevation of TG by AA was the
result, at least partly, of PPARg activation, and AA takes
part in TG formation as demonstrated by the elevation of
AA-containing species among the total TG.
It is known that in sebocytes RSG also induced CH
accumulation (Trivedi et al, 2006). In our data, inhibition of
PPARg also lowered the basal level of CH. However, AA did
not have an effect on CH level. It is likely that, under our
experimental conditions, AA caused remodelling of lipid
species bearing FA side chains, such as glycerophospholipids
and TG, and affected minimally the non-esterified lipid
components. Taken together, these data suggest that TG and
CH production is likely to be regulated by PPARg in sebocytes.
It is also likely that pathways leading to neutral lipid formation
were regulated by AA in a lipid species–selective manner.
AA treatment also causes PPARg-dependent elevation of
some minor lipids, such as LPC and PIs (Figure 3c). In
sebocytes, LPC is a minor phospholipid in membranes of lipid
droplets consisting of monolayer phospholipids (Corsini et al.,
2003). Lipid droplets in a wide range of cell lines (i.e.,
adipocytes, keratinocytes) were shown to be involved both
in deposition and storage of neutral lipids (Brasaemle et al.,
1997; Heid et al., 1998) and were shown to have ADRP
protein on their surface. These data might indicate that PPARg
is involved in the formation of these lipid droplets, i.e., neutral
lipid storage or production.
AA also significantly decreased the level of PIs in a PPARg-
dependent manner, suggesting that enzymes which are
involved in the synthesis/degradation of PIs are also influenced
by the receptor. The altered level of PIs, based on their
versatile roles in various biological processes, might influence
several functions of sebocytes, i.e., PIs are essential phospho-
lipids in the formation of cellular membranes. Moreover, one
group of their metabolic products, phosphoinositides, are key
signal transduction molecules. The IP3 (inositol 1,4,5-trispho-
sphate 3) kinase pathway has a common part with the MAPK
(mitogen-activated protein kinase)-induced pathway, which
was shown to be involved in AEA-induced sebaceous lipid
synthesis, in which PPARg also has a role (Dobrosi et al.,
2008).
Phopholipase A2 (PLA2) is the enzyme responsible for
hydrolyzing fatty acids like AA from glycerophospholipids
(Scott, 1997). Therefore they represent the source for AA
production. PLA2 was detected in various cells of the skin and
also in SZ95 sebocytes (Schagen et al., 2008) and treatment
with active PLA2 increased neutral and polar lipid production
of sebocytes (Schagen et al., 2008). It seems possible, that
PLA2 is one regulator of endogenous AA production in
sebocytes, and it also determines the level of PPARg
activation in these cells, at least in part. The identification of
endogenous AA metabolites (such as 5-KETE, 12-KETE) by us
supports this scenario. In addition, the reduction of the PI’s
level also suggests that there is a feedback mechanism aimed
at the regulation of AA production if it is exogenously added.
Although PPARg probably controls both the levels of major
neutral lipids and levels of LPC and PIs, the exact mechanism
of action in sebaceous differentiation remains to be
discovered.
Another key goal of our study was to identify endogenous
ligands. Various AA metabolites have been described as
natural PPARg ligands in the skin (Weindl et al., 2005),
adipocytes (Oster et al., 2010), cardiomyocytes (Hovsepian
et al., 2010), and in several types of cancers (Dionne et al.,
2010; Li et al., 2010; Maggiora, et al., 2010). We found that
the AA keto-metabolites (5-KETE and 12-KETE) act as
endogenous PPARg ligands in SZ95 sebocytes as they
elevated sebaceous lipid synthesis in a PPARg-dependent
manner (Figure 4b–e).
In summary, our study provides evidence that PPARg
participates in the signaling mechanisms of sebocyte differ-
entiation. We also demonstrated that AA-activated PPARg is
involved in the regulation of major neutral lipid and phos-
pholipid biosynthesis. Finally, we presented that PPARg is
activated by AA keto-metabolites (5-KETE, 12-KETE). Taken
together, our data implicate that AA-activated PPARg is an
important regulator of differentiation and lipid metabolism in
human sebocytes; therefore PPARg might be a potential
therapeutic target molecule in sebaceous dermatoses.
MATERIALS AND METHODS
Detailed description of the techniques used can be found in
Supplementary Data online.
Cell culturing
Human immortalized sebocytes were cultured according to pre-
viously described protocol. (Zouboulis et al., 1999).
Determination of intracellular lipids
For quantitative measurement of lipid content, SZ95 sebocytes
(10,000 cells/well) were cultured in 96-well black-well/clear-bottom
plates (Greiner Bio-One, Frickenhausen, Germany) in quadruplicates
and were treated with compounds for 24 hours. Then, cells were
stained with 1mg ml 1 Nile red (Sigma-Aldrich, St Louis, MO) and
incubated at 37 1C for 20 minutes. Fluorescence was measured on a
Molecular Devices FlexStation384 II Fluorescence Image Microplate
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Reader (FLIPR, Molecular Devices, San Francisco, CA). Results were
expressed as percentages of the relative fluorescence units in
comparison with the controls using 485 nm excitation and 565 nm
emission wavelengths for neutral lipids and 540 nm excitation and
620 nm emission wavelength for polar lipids (Alestas et al., 2006;
Toth et al., 2009). Mean±SD of quadruplicate determinations is
shown. Experiments were repeated three times.
Determination of lipid species by ESI-MS/MS, HPTLC, and
HPLC-MS
The composition of neutral lipids was investigated in SZ95 sebocytes
based on the HPTLC and HPLC-MS with a time of flight MS detector
(HPLC-ToF/MS) analyses of WE, TG, DG, CE, CH, FFA, and SQ
(Camera et al., 2010; Fuchs et al. 2011). Quantitative determinations
of AA, SQ, and CH were performed with a triple quadrupole mass
detector (QqQ) following HPLC separation (Camera et al., 2010). The
HPLC-MS systems were from Agilent Technologies (Waldbronn,
Germany). For quantitative measurement of nine membrane lipid
classes in SZ95 sebocytes (PI, LPC, SPM, dhSPM, PE, PS, PG, CER,
gluCER), direct flow injection ESI-MS/MS in positive ion mode was
applied, using the analytical setup and strategy described previously
(Liebisch et al., 1999, 2004, 2006; Zemski Berry and Murphy, 2004).
Detemination of eicosanods using HPLC-MS-MS methodology
For quantitative determination of eicosanoids and docosanoids in
treated SZ95 cells, the HPLC-MS-MS methodology was used; the
analytical sample preparation procedure is based on an established
method used for retinoid quantification (Ru¨hl et al., 2006) and was
recently published for organs and serum analysis (Szklenar et al.,
2013 in press).
RNA isolation, real-time quantitative PCR
Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Reverse transcription was
performed at 42 1C for 30 minutes, using Superscript II reverse
transcriptase (Invitrogen). Quantitative PCR was performed on an
ABI PRISM 7900 instrument (Applied Biosystems, Foster City, CA), 40
cycles of 95 1C for 12 seconds, and 60 1C for 1 minute using TaqMan
assays (Applied Biosystems). All PCR reactions were performed in
triplicates with one control containing no reverse transcriptase
enzyme. The comparative Ct method was used to quantify transcripts
and normalize for human cyclophilin A. Mean and SD were
calculated for both the normalized and the normalizer values for all
experiments. Data shown are mean±SD of three biological replicates
measured in triplicates. *Po0.05 was considered as significant
change compared with vehicle-treated control or ligand-treated cells.
Statistical analysis
When applicable, data were analyzed using a two tailed un-paired
t-test (Figure 1d, Figure 4a), and values of Po0.05 were regarded as
significant. In addition, statistical differences were further verified
using one-way analysis of variance with Bonferroni’s and Dunnett’s
post hoc probes, resulting in similar results (Figures 2b–e, 3a–d, and
4b–e, Supplementary Figure S1b online).
Patient samples
The study was approved by the Institutional Research Ethics Com-
mittee and adhered to the Declaration of Helsinki Guidelines.
Formalin-fixed, paraffin-embedded tissues were obtained from the
archive files of the Departments of Dermatology and Pathology,
University of Debrecen, Debrecen, Hungary. The human tissue
samples were all handled as anonymous in respect of patients’
dignity.
Immunohistochemistry and double immunofluorescence
Immunohistochemistry for PPARg was carried out using the biotin-
free and tyramid-based CSAII kit (Dako, Glostrup, Denmark) accord-
ing to the manufacturer’s instruction and as described previously
(Szanto et al., 2004; Szatmari et al., 2006; Gogolak et al., 2007).
Single immunohistochemical staining for AR and p63 and Ki67 were
all detected with standard immune-peroxidase method using an
EnVisionþ -HRP (horseraddish-peroxidase) detection kit or an
automated immune-stainer (Bond-Leica, Newcastle, UK) utilizing
VIP (purple) or DAB (brown) chromogenic substrates for micro-
scopic visualisation. The immunostained slides were then evaluated
semi-quantitatively for distinct SGs/SG tumors reflecting the
percentage of positive cells:  , negative; 1þ , 0–20%; 2þ , 20–
50%; 3þ , 50–75%; and 4þ , 75–100%.
Laser capture microdissection and RNA preparation
Serial cryosections were then made and mounted onto sterile
membrane-containing microscopic slides (Jenkins et al., 2005).
Compartments of SGs were in situ laser-microdissected (MMI-
Olympus LCM system, Glattbrugg, Switzerland) and collected separa-
tely from the surrounding dermal tissue (Supplementary Figure S1c
online). Then, Absolutely Nanoprep RNA isolation kit (Stratagene,
La Jolla, CA) was used according to the vendor’s protocol. Samples
were stored at  70 1C until use.
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